Study: Direct-to-consumer drug ads can be misleading

Drugmakers have taken a lot of flack over direct-to-consumer drug advertising, but to date, Congress hasn't imposed any major limitations on the practice. Critics have argued that such ads encourage the use of costly new drugs over equally-effective generics. And those critics aren't going away anytime soon, it seems, especially if studies like these keep coming.

The latest challenge to DTC drug ads comes from researchers with the University of California, Los Angeles. The research team, led by clinical psychologist Dominick L. Frosch, concluded that American TV viewers see as many as 16 hours of prescription drug advertisements every years.

The study found that DTC drug advertisements aren't doing much to help consumers make better health decisions, either. With commercials featuring emotional portrayals of drug benefits, and risk messages obscured by happy imagery, consumers can easily be mislead, suggests the study.

Moreover, most ads don't provide enough information to help consumers determine whether the drug would help them, according to the study, which is published in the American Journal of Public Health.

To learn more about the study:
- read this UPI piece

Related Articles:
FDA should regulate medical devicemakers' DTC advertising
Who will pay for DTC pharma ad oversight?
Drugmakers agree to six-month DTC delay

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.